Cytokinetics Inc. (CYTK) Sank To Over A 2-Month Low On Study Results Cytokinetics Inc. (CYTK) and Amgen (AMGN) announced Tuesday that data from the ATOMIC-AHF Phase 2 study did not meet its primary endpoint of dyspnea response as measured by the 7-point Likert scale through 48 hours.
Sept. 4, 2013 - RTT News
Cytokinetics Inc. (CYTK) Is Down Sharply On Study Results Cytokinetics Inc. (CYTK) and Amgen (AMGN) announced Tuesday that data from the ATOMIC-AHF Phase 2 study did not meet its primary endpoint of dyspnea response as measured by the 7-point Likert scale through 48 hours.
Sept. 3, 2013 - RTT News
CYTK To Take A Hit, Tune Into ESPR, Watch Out For HALO Effect A phase II trial evaluating Cytokinetics Inc.'s (CYTK) drug candidate Omecamtiv mecarbil in intravenous formulation as a potential treatment of heart failure, dubbed ATOMIC-AHF, has failed to meet its primary endpoint of dyspnea (shortness of breath) but has shown favorable dose and concentration-related trends on dyspnea response.
Sept. 3, 2013 - RTT News